EU OKs first treatment for ultra rare lysosomal storage disorder

Ultragenyx’ Mepsevii has been cleared for use in Europe to treat the ultra rare disease mucopolysaccharidosis type VII (MPS VII), offering patients an approved treatment for the very first time.Original Article